eIF4E Inhibitors

The chemical class of eIF4E inhibitors encompasses a diverse set of compounds designed to modulate the activity or expression of eIF4E, a key player in the initiation of cap-dependent translation. These inhibitors interfere with various stages of the eIF4E-mediated translation process, employing distinct mechanisms to regulate its function. Compounds like Ribavirin, 4EGI-1, 4E1RCat, Sorafenib, and Rapamycin each impact eIF4E through different avenues. Ribavirin, known as an antiviral drug, inhibits eIF4E function, impeding the translation of specific mRNAs, while 4EGI-1 and 4E1RCat disrupt the interaction between eIF4E and eIF4G, crucial for translation initiation. Furthermore, compounds like Metformin, Perifosine, Cercosporamide, CGP57380, Ellipticine, Flavopiridol, and Propafenone each showcase unique mechanisms affecting eIF4E. Metformin, commonly used for type 2 diabetes, and Perifosine down-regulate eIF4E in certain cellular contexts. Cercosporamide inhibits Mnk1/2 kinases, leading to decreased eIF4E phosphorylation and activity, while CGP57380 specifically targets Mnk1, preventing eIF4E phosphorylation and activation. Ellipticine and Flavopiridol, natural alkaloids and a cyclin-dependent kinase inhibitor, respectively, down-regulate eIF4E expression, showcasing the diversity of compounds that modulate eIF4E at various levels. Propafenone, an antiarrhythmic agent, has been identified as an eIF4E inhibitor in screenings, expanding the repertoire of compounds that affect eIF4E function.